Activating ERBB4 mutations in non-small cell lung cancer

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Non-small cell lung cancer (NSCLC) characterization reveals frequent ERBB4 mutations.
• The functional significance of mutated ERBB4 in NSCLC is not well understood.

Purpose of the Study:

• To functionally characterize nine ERBB4 mutations found in lung adenocarcinoma.
• To investigate the impact of these mutations on ERBB4 activity, dimerization, and downstream signaling.

Main Methods:

• Functional characterization of nine ERBB4 mutations.
• Assessment of ErbB4 phosphorylation, dimerization, and trans-activation.
• Analysis of NIH 3T3 cell survival and downstream signaling pathway activation (Erk1/2, Akt).
• Evaluation of ErbB4 intracellular domain release.

Main Results:

• Four ERBB4 mutations (Y285C, D595V, D931Y, K935I) were identified as activating.
• These activating mutations increased basal and ligand-induced ErbB4 phosphorylation and dimerization.
• Mutant ERBB4 enhanced cell survival and proteolytic release of its intracellular domain.
• Canonical pathway effector phosphorylation was only moderately increased, suggesting alternative signaling mechanisms.

Conclusions:

• Activating mutations in ERBB4 are present in non-small cell lung cancer.
• These mutations promote ERBB4 dimerization, signaling, and cell survival.
• ERBB4 mutations may act as driver mutations in lung adenocarcinoma.